Banco Bilbao Vizcaya Argentaria, S.A. vs F. Hoffmann-La Roche AG: Strategic Comparison

This in-depth comparison examines Banco Bilbao Vizcaya Argentaria, S.A. and F. Hoffmann-La Roche AG across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Banco Bilbao Vizcaya Argentaria, S.A. on its own, evaluating F. Hoffmann-La Roche AG, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Banco Bilbao Vizcaya Argentaria, S.A. and F. Hoffmann-La Roche AG is widest.

On the headline numbers, Banco Bilbao Vizcaya Argentaria, S.A. reports annual revenue of ~$41.7B against ~$73.8B for F. Hoffmann-La Roche AG, while their respective market capitalizations stand at $139.7B and $355.0B. Banco Bilbao Vizcaya Argentaria, S.A. is headquartered in Spain and F. Hoffmann-La Roche AG in Switzerland, and those different home markets shape how each company competes.

Banco Bilbao Vizcaya Argentaria, S.A.: BBVA is a Spanish banking group that earns more abroad than at home. It is Spain's second-largest bank, but Mexico produced ~$5.95B (EUR5.264B) of its ~$11.9B (EUR10.511B) net attributable profit in 2025, with Turkey, Colombia, Peru, Argentina, Uruguay and a corporate and investment banking arm making up the rest. The group employed 127,174 people at the end of 2025 and served 81.2 million active customers.

F. Hoffmann-La Roche AG: Roche Holding AG is a Swiss healthcare company headquartered in Basel and listed on the SIX Swiss Exchange (ROG non-voting equity securities and RO bearer shares; RHHBY ADRs in the US). It is one of the largest pharmaceutical companies by sales and the largest in vitro diagnostics supplier. Key subsidiaries include Genentech in the US, Chugai Pharmaceutical in Japan and Foundation Medicine.

Banco Bilbao Vizcaya Argentaria, S.A. and F. Hoffmann-La Roche AG pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Banco Bilbao Vizcaya Argentaria, S.A. and F. Hoffmann-La Roche AG.

Banco Bilbao Vizcaya Argentaria, S.A. business model: BBVA runs a universal banking model built on local subsidiaries that fund themselves with local deposits, so a shock in one country does not drain the parent. Customer deposits reached ~$568B (EUR502.5B) at the end of 2025 against ~$534B (EUR472.7B) of gross loans, and net interest income of ~$29.7B (EUR26.280B) provided about 71 percent of gross income. Fees from payments, cards, asset management and insurance added ~$9.28B (EUR8.215B) and net trading income ~$3B (EUR2.656B). Distribution is mostly digital: 81.2 million active customers were served through 5,642 branches and 31,015 ATMs, and the efficiency ratio of 38.8 percent is one of the lowest among large European banks.

F. Hoffmann-La Roche AG business model: Roche makes money in two ways. The Pharmaceuticals Division (~$57.2 billion (CHF 47.7 billion) in 2025) sells patented medicines, mostly biologics, in oncology, neuroscience, immunology, ophthalmology and haemophilia; top growth drivers in 2025 were Phesgo, Xolair, Ocrevus, Hemlibra and Vabysmo. The Diagnostics Division (~$16.6 billion (CHF 13.8 billion)) places cobas, Elecsys and Ventana instruments in laboratories and earns recurring revenue from the reagents, tests and service contracts needed to run them. Companion diagnostics link the two: a Roche test can identify the patients most likely to benefit from a Roche drug.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Banco Bilbao Vizcaya Argentaria, S.A. stack up against those of F. Hoffmann-La Roche AG.

Banco Bilbao Vizcaya Argentaria, S.A. competitive advantage: BBVA's first advantage is scale in Mexico, where BBVA Mexico is the largest bank in the country and produced ~$5.95B (EUR5.264B) of net attributable profit in 2025, close to half the group total. The second is cost: operating expenses grew 1.0 percent in euros in 2025 while gross income grew 4.1 percent, holding the efficiency ratio at 38.8 percent with a branch network trimmed to 5,642 offices. Group ROTE of 19.3 percent is a level BBVA describes as leading among large European banks.

F. Hoffmann-La Roche AG competitive advantage: Roche's edge comes from three things: scale in both drugs and diagnostics, a long-horizon ownership structure, and a federated R&D model. The Hoffmann and Oeri family pool holds the majority of voting shares, which shields management from takeover pressure. Research runs through separate centres (Genentech gRED in South San Francisco, pRED in Basel and majority-owned Chugai in Japan), and the company spent ~$14.6 billion (CHF 12.2 billion) on core R&D in 2025.

Future prospects matter as much as current results. The growth strategies below explain how Banco Bilbao Vizcaya Argentaria, S.A. and F. Hoffmann-La Roche AG each plan to expand from here.

Banco Bilbao Vizcaya Argentaria, S.A. growth strategy: After the Banco Sabadell offer lapsed in October 2025, BBVA's growth plan rests on organic lending, digital expansion in Europe and capital returns. Loans and advances to customers grew 11.5 percent in 2025 and customer funds 13.5 percent. The group opened a branch-free digital bank in Italy in October 2021, which passed 800,000 customers by its fourth anniversary and targets one million during 2026, and launched a second digital bank in Germany in June 2025. Capital released by the 2021 transfer of BBVA USA to PNC still underpins buybacks and dividends, with half of 2025 profit earmarked for shareholders.

F. Hoffmann-La Roche AG growth strategy: Roche is building a cardiovascular, renal and metabolic franchise through acquisitions of Carmot Therapeutics (2023, $2.7 billion upfront) and 89bio (2025, up to about $3.5 billion), the petrelintide partnership with Zealand Pharma, and a new Innovation Center in Boston opened in September 2026. It is also extending its immunology pipeline via Telavant (2023, $7.1 billion) and investing in AI diagnostics with the PathAI acquisition announced in May 2026 ($750 million upfront plus up to $300 million in milestones).

A closer look at the financial trajectory of Banco Bilbao Vizcaya Argentaria, S.A. and F. Hoffmann-La Roche AG rounds out the comparison.

Banco Bilbao Vizcaya Argentaria, S.A.: BBVA's profit is spread across five business areas. In 2025 Spain contributed ~$4.72B (EUR4.175B) of net attributable profit, Mexico ~$5.95B (EUR5.264B), Turkey ~$910M (EUR805M), South America ~$820M (EUR726M) and Rest of Business ~$709M (EUR627M), while the Corporate Center recorded a ~$1.23B (EUR1.086B) loss. Gross income rose 4.1 percent in reported euros but 16.3 percent at constant exchange rates, the gap being mostly the weaker Mexican peso. Loan-loss impairments were ~$6.86B (EUR6.073B) with a cost of risk of 1.39 percent, and the NPL ratio improved to 2.7 percent with 85 percent coverage. CET1 capital closed at 12.70 percent against a 9.28 percent requirement, and BBVA set total 2025 shareholder distributions at 50 percent of profit, EUR0.92 per share in cash.

F. Hoffmann-La Roche AG: Roche's 2025 group sales were ~$73.8 billion (CHF 61.5 billion), up 7% at constant exchange rates but only 2% in Swiss francs. Core operating profit grew 13% CER to ~$26.2 billion (CHF 21.8 billion), core EPS was CHF 19.46, and IFRS net income jumped to ~$16.6 billion (CHF 13.8 billion) from ~$11 billion (CHF 9.2 billion) in 2024, when impairments depressed profit. In H1 2026 core operating margin widened 1.7 points to 39.0%, while a strong franc pushed reported sales down 2%. The board raised the dividend to CHF 9.80, the 39th consecutive increase, and guided for mid-single-digit CER sales growth and high-single-digit core EPS growth in 2026.